Why the study?
Does olmesartan reduce blood pressure and inflammation markers more than telmisartan in Japanese early-stage type-2 diabetics with hypertension?
Does olmesartan reduce blood pressure and inflammation markers more than telmisartan in Japanese early-stage type-2 diabetics with hypertension?
In Japanese patients with early-stage type-2 diabetes and hypertension, olmesartan provides greater blood pressure reduction and anti-inflammatory effects compared to telmisartan.
No takes yet. Share an insight, caveat, or question.
May favor olmesartan for BP and inflammation control in this cohort; leaves open need for randomized confirmation.
Nakayama et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: